Tariq Mughal – författare

With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.

This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.

A brand-new edition of the bestselling guide to hematologic malignancies.

An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.

Following on the successful steps of the first edition, this Second Edition covers:

Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.

Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.